TBI-1301 + Cyclophosphamide + Fludarabine
Phase 3RecruitingInterest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Synovial Sarcomas
Conditions
Synovial Sarcomas
Trial Timeline
Jan 5, 2026 → Mar 1, 2032
NCT ID
NCT07174427About TBI-1301 + Cyclophosphamide + Fludarabine
TBI-1301 + Cyclophosphamide + Fludarabine is a phase 3 stage product being developed by Takara Bio for Synovial Sarcomas. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07174427. Target conditions include Synovial Sarcomas.
What happened to similar drugs?
1 of 3 similar drugs in Synovial Sarcomas were approved
Approved (1) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07174427 | Phase 3 | Recruiting |
Competing Products
8 competing products in Synovial Sarcomas
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pexidartinib | Daiichi Sankyo | Phase 2 | 39 |
| Pexidartinib | Daiichi Sankyo | Phase 3 | 44 |
| Pexidartinib | Daiichi Sankyo | Approved | 43 |
| Ramucirumab + Gemcitabine + Docetaxel | Eli Lilly | Phase 1/2 | 24 |
| LV305 + G305 | Merck | Phase 3 | 32 |
| TBI-1301 + Cyclophosphamide | Takara Bio | Phase 1/2 | 32 |
| FHD-609 | Foghorn Therapeutics | Phase 1 | 11 |
| CFT8634 | C4 Therapeutics | Phase 1 | 11 |